Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Related Articles by Review for PubMed (Select 21756013)

1.

Identifying favorable-value cardiovascular health services.

Braithwaite RS, Mentor SM.

Am J Manag Care. 2011 Jun;17(6):431-8. Review.

2.

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.

Heeg B, Damen J, Van Hout B.

Pharmacoeconomics. 2007;25(12):1063-82. Review.

PMID:
18047390
3.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

4.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

5.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

6.

Screening for type 2 diabetes: literature review and economic modelling.

Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.

7.

Prevention of cardiovascular events in elderly people.

Andrawes WF, Bussy C, Belmin J.

Drugs Aging. 2005;22(10):859-76. Review.

PMID:
16245959
8.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

9.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

10.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

11.

Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.

Law M, Wald N, Morris J.

Health Technol Assess. 2003;7(31):1-94. Review.

12.
13.

The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.

Skedgel C, Goeree R, Pleasance S, Thompson K, O'brien B, Anderson D.

J Bone Joint Surg Am. 2007 Apr;89(4):819-28. Review.

PMID:
17403806
14.

Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction.

Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, Fraser C, McKenzie L, Gemmell H, Hillis G, Metcalfe M.

Health Technol Assess. 2004 Jul;8(30):iii-iv, 1-207. Review.

15.
16.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
17.

Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.

Lynd LD, O'Brien BJ.

J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S99-103. Review.

PMID:
12950529
18.

A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.

Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E.

Med Decis Making. 2007 Nov-Dec;27(6):789-821. Review.

PMID:
18057191
19.

The economics of cardiovascular disease in the United States.

Chen J, Rizzo JA.

Crit Care Clin. 2012 Jan;28(1):77-88, vi. doi: 10.1016/j.ccc.2011.10.007. Review.

PMID:
22123100
20.

Cost-effectiveness and future implications for cardiovascular imaging.

Shaw LJ.

Can J Cardiol. 2013 Mar;29(3):350-7. doi: 10.1016/j.cjca.2012.10.017. Epub 2013 Jan 16. Review.

PMID:
23332968
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk